NUTROPIN AQ NUSPIN (somatropin) by Roche. Approved for recombinant human growth hormone [epc]. First approved in 1995.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
NUTROPIN AQ NUSPIN is a recombinant human growth hormone (somatropin) administered by injection for growth hormone deficiency and related growth disorders. It is a biologic therapeutic that replaces or supplements endogenous growth hormone to promote normal growth and development in pediatric and adult patients.
With $6M in Part D spending and approaching loss of exclusivity, this product is in a defensive phase with potential for team restructuring and transition planning.
Recombinant Human Growth Hormone
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature
Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin (Somatropin) Delivery and Taken up Into the Blood in Healthy Adults
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Worked on NUTROPIN AQ NUSPIN at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on NUTROPIN AQ NUSPIN offers experience in mature biologic portfolio management, competitive dynamics, and LOE transition strategies within a specialized endocrinology space. Career growth depends on strategic repositioning and cross-functional collaboration to defend market share against biosimilar and generic competition.